论文部分内容阅读
随着大众健康意识的增强和超声诊断水平的提高,甲状腺微小乳头状癌(PTMC)在全部甲状腺癌中的占比越来越高,在部分大医院已经占全部甲状腺癌的75%左右。这类患者的不断增多,使得社会大众和医学业界对于PTMC的诊疗高度关注,也使得原本相对已经达成共识的诊疗原则不断被质疑,围绕PTMC的诊断和治疗,近几年争议突起。现就主要的争议话题和相关临床证据进行讨论,以期将争议引入到更为客观、科学、理性的轨道上来。
With the enhancement of public health awareness and the improvement of ultrasound diagnosis, the proportion of thyroid papillary carcinoma (PTMC) in all thyroid cancer is getting higher and higher, accounting for about 75% of the total thyroid cancer in some large hospitals. The increasing number of these patients has caused the public and the medical community to pay close attention to the treatment of PTMC. It has also led to the fact that the relative principles of diagnosis and treatment have been constantly questioned. In recent years, there has been controversy over the diagnosis and treatment of PTMC. The main topic of controversy and relevant clinical evidence are discussed in order to bring the controversy to a more objective, scientific and rational track.